PH30120A - Stable pharmaceutical composition of fumagillol derivatives - Google Patents

Stable pharmaceutical composition of fumagillol derivatives

Info

Publication number
PH30120A
PH30120A PH47449A PH47449A PH30120A PH 30120 A PH30120 A PH 30120A PH 47449 A PH47449 A PH 47449A PH 47449 A PH47449 A PH 47449A PH 30120 A PH30120 A PH 30120A
Authority
PH
Philippines
Prior art keywords
pharmaceutical composition
stable pharmaceutical
fumagillol derivatives
fumagillol
derivatives
Prior art date
Application number
PH47449A
Other languages
English (en)
Inventor
Shigeo Yanai
Kazuhiro Saito
Hiroaki Okada
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of PH30120A publication Critical patent/PH30120A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
PH47449A 1992-12-16 1993-12-15 Stable pharmaceutical composition of fumagillol derivatives PH30120A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33582892 1992-12-16

Publications (1)

Publication Number Publication Date
PH30120A true PH30120A (en) 1996-12-27

Family

ID=18292862

Family Applications (1)

Application Number Title Priority Date Filing Date
PH47449A PH30120A (en) 1992-12-16 1993-12-15 Stable pharmaceutical composition of fumagillol derivatives

Country Status (8)

Country Link
US (1) US5422363A (enExample)
EP (1) EP0602586B1 (enExample)
KR (1) KR940013499A (enExample)
CN (1) CN1093901A (enExample)
AT (1) ATE153854T1 (enExample)
CA (1) CA2111560A1 (enExample)
DE (1) DE69311278T2 (enExample)
PH (1) PH30120A (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5566069A (en) * 1994-03-07 1996-10-15 Monsanto Company Computer network for collecting and analyzing agronomic data
US5699244A (en) * 1994-03-07 1997-12-16 Monsanto Company Hand-held GUI PDA with GPS/DGPS receiver for collecting agronomic and GPS position data
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
US20010025046A1 (en) * 1999-06-24 2001-09-27 Rong(Ron) Liu Self-emulsifying systems containing anticancer medicament
DK1156829T3 (da) 1999-02-26 2007-09-10 Sanofi Aventis Stabil formulering indeholdende fumagillin
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
US7105482B2 (en) * 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
US6548477B1 (en) * 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US7084108B2 (en) * 2000-11-01 2006-08-01 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6919307B2 (en) * 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US7001603B2 (en) * 2001-02-28 2006-02-21 Color Access, Inc. Gelled two phase cosmetic compositions
KR100451485B1 (ko) * 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
CA2550873A1 (en) * 2003-12-29 2005-07-21 Praecis Pharmaceuticals, Inc. Inhibitors of methionine aminopeptidase-2 and uses thereof
EA020251B1 (ru) * 2007-11-28 2014-09-30 Мерсана Терапьютикс, Инк. Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина
CA2731020A1 (en) 2008-07-18 2010-01-21 Zafgen, Inc. Use of antiangiogenic fumagillins in the treatment of obesity
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
KR20120083905A (ko) 2009-10-09 2012-07-26 자프겐 코포레이션 비만의 치료에 사용하기 위한 설폰 화합물
CA2786603C (en) 2010-01-08 2018-02-20 James E. Vath Fumagillol type compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
US20130023513A1 (en) 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
KR20130043207A (ko) 2010-07-22 2013-04-29 자프겐 인크. 트리시클릭 화합물 및 이의 제조 및 사용 방법
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
US20140073691A1 (en) 2010-11-10 2014-03-13 Zafgen, Inc. Methods and composition for Treating Thyroid Hormone Related Disorders
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
CA2819251A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
CA2825408A1 (en) 2011-01-26 2012-08-02 Zafgen, Inc. Tetrazole compounds and methods of making and using same
JP5876513B2 (ja) 2011-03-08 2016-03-02 ザフゲン，インコーポレイテッド オキサスピロ［２．５］オクタン誘導体および類似体
BR112013028665A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
KR101979039B1 (ko) 2011-05-06 2019-05-15 자프겐 인크. 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
BR112013028666A2 (pt) 2011-05-06 2017-08-08 Zafgen Inc compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
EP2804856B1 (en) 2012-01-18 2017-03-15 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
EP2847176A1 (en) 2012-05-07 2015-03-18 Zafgen, Inc. Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same
BR112014028041A2 (pt) 2012-05-08 2017-06-27 Zafgen Inc tratamento de obesidade hipotalâmica com inibidores de metap2
CA2873574A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumagillol type compounds and methods of making and using same
CN104918615B (zh) 2012-11-05 2018-10-12 扎夫根股份有限公司 治疗肝病的方法
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
US9868717B2 (en) 2012-11-05 2018-01-16 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
AU2014236528A1 (en) 2013-03-14 2015-09-24 Zafgen, Inc. Methods of treating renal disease and other disorders
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
JP6908769B2 (ja) 2017-03-15 2021-07-28 セレシン・インコーポレーテッド 高い薬物充填量の中鎖脂肪酸トリグリセリドを有する医薬組成物およびそれに関連する方法
BE1027390B1 (nl) * 2019-06-21 2021-02-02 Nutrition Sciences Nv Mfca-samenstelling voor gebruik in de aquacultuur van schaaldieren

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
CA1333363C (en) * 1988-01-19 1994-12-06 Judah Folkman Angiogenesis inhibitor comprising fumagillin
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
US4954496A (en) * 1988-08-12 1990-09-04 Fujisawa Pharmaceutical Company, Ltd. Cyclohexane derivatives and pharmaceutical compositions
ATE106726T1 (de) * 1988-09-01 1994-06-15 Takeda Chemical Industries Ltd Angiogenese hemmendes mittel.
EP0359036B1 (en) * 1988-09-01 1997-03-26 Takeda Chemical Industries, Ltd. Fumagillol derivatives
EP0387650B1 (en) * 1989-03-06 1993-03-31 Takeda Chemical Industries, Ltd. 6-epifumagillols, production and use thereof
DE69004598T2 (de) * 1989-03-06 1994-03-24 Takeda Chemical Industries Ltd 6-Amino-6-desoxyfumagillole, ihre Herstellung und ihre Verwendung.
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (enExample) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
US5202352A (en) * 1990-08-08 1993-04-13 Takeda Chemical Industries, Ltd. Intravascular embolizing agent containing angiogenesis-inhibiting substance

Also Published As

Publication number Publication date
CA2111560A1 (en) 1994-06-17
EP0602586A3 (enExample) 1994-08-31
EP0602586B1 (en) 1997-06-04
ATE153854T1 (de) 1997-06-15
DE69311278T2 (de) 1997-10-30
US5422363A (en) 1995-06-06
KR940013499A (ko) 1994-07-15
EP0602586A2 (en) 1994-06-22
CN1093901A (zh) 1994-10-26
DE69311278D1 (de) 1997-07-10

Similar Documents

Publication Publication Date Title
PH30120A (en) Stable pharmaceutical composition of fumagillol derivatives
CA2156288A1 (en) Glycerol derivative, device and pharmaceutical composition
MA22733A1 (fr) Esters citrates acyles en tant que precurseurs de peracides.
NO934499D0 (no) Ikke-klorfluorcarbonaerosolformuleringer
NO911591L (no) Fremgangsmaate for fremstilling av sukrose-6-ester.
PL309812A1 (en) Derivatives of 2-(2-amino- 1,6-dihydro-6-oxopurin-9-ylo) - methoxy-1,3-propanodiole, method of obtaining them and pharmaceutical composition containing such derivatives
ITRM920761A1 (it) Esteri della l-carnitina e di alcanoil l-carnitine con l'acido glicolico o suoi esteri e composizioni farmaceutiche contenenti tali per il trattamento di affezioni cutanee.
NO176082C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat inneholdende bunazosin, for perkutan tilförsel
MY114765A (en) Preparation for epidermis
FI905748A0 (fi) Foerfarande foer framstaellning av 4-o -fosfater av dopamin och dopaminderivat.
EP0666865A4 (en) PLANT FATTY ACID SYNTHASES.
DK0563112T3 (da) Probucol-holdigt lægemiddel med forøget biotilgængelighed
ATE120730T1 (de) 3.3'-dithiobis (propionsäuren) und estern davon.
KR860700122A (ko) 데글루코테이코플라닌의 카트복실산 에스테르 유도체
MY106615A (en) Stabilized leukocyte-interferons.
GR3006732T3 (enExample)
NO171912C (no) Fremgangsmaate for fremstilling av 5-klor-3-klorsulfonyl-2-tiofenkarboksylsyreestere
FR2687667B1 (fr) Esters d'acides carboxyliques d'hydroxyphenylalcanols comme stabilisants.
EP0643054A3 (en) Process for the preparation of carbonic acid ester derivatives and intermediates.
FI905930A7 (fi) Menetelmä uusien, farmakologisesti käyttökelpoisten bispilokarpiinihapon esterijohdannaisten valmistamiseksi
BE895712A (fr) Derives de benzo-1,3-thiazine-1,1-dixoyde, leur preparation et leur utilisation
SE8104657L (sv) Injicerbara farmaceutiska kompositioner
OA06793A (fr) Procédé de préparation de dérivés esters d'acides cyclopropane-carboxyliques.
GB9004857D0 (en) Flame retardant compounds and compositions containing them
BE894245A (fr) Derives d'esters de n-arylsulfinyl-n-phosphonomethylglycinates